Cancer-specific mutations in phosphatidylinositol 3-kinase
- PMID: 17561399
- DOI: 10.1016/j.tibs.2007.05.005
Cancer-specific mutations in phosphatidylinositol 3-kinase
Abstract
Cancer-specific mutations in the catalytic subunit of phosphatidylinositol 3-kinase (PI3K) p110 alpha occur in diverse tumors in frequencies that can exceed 30%. The majority of these mutations map to one of three hot spots in the gene, and the rest are distributed over much of the PI3K coding sequence. Most of the cancer-specific mutations induce a gain of function that results in oncogenicity, elevated lipid kinase activity and constitutive signaling through the kinases Akt and TOR. The location of the mutations on a model structure of p110 alpha indicates several distinct mechanisms for the gain of function. The mutated p110 alpha proteins are promising cancer targets. Although identification of mutant-specific small-molecule inhibitors seems technically challenging, the therapeutic benefits from such inhibitors could be extremely important.
Similar articles
-
Biochemical and biological characterization of tumor-associated mutations of p110alpha.Methods Enzymol. 2008;438:291-305. doi: 10.1016/S0076-6879(07)38020-8. Methods Enzymol. 2008. PMID: 18413256
-
NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.Cancer Res. 2008 Oct 1;68(19):8022-30. doi: 10.1158/0008-5472.CAN-08-1385. Cancer Res. 2008. PMID: 18829560
-
Phosphoinositide 3-kinase: from viral oncoprotein to drug target.Virology. 2006 Jan 5;344(1):131-8. doi: 10.1016/j.virol.2005.09.027. Virology. 2006. PMID: 16364744 Review.
-
Involvement of the p110 alpha isoform of PI3K in early development of mouse embryos.Mol Reprod Dev. 2009 Apr;76(4):389-98. doi: 10.1002/mrd.20978. Mol Reprod Dev. 2009. PMID: 18932194
-
Drug discovery approaches targeting the PI3K/Akt pathway in cancer.Oncogene. 2008 Sep 18;27(41):5511-26. doi: 10.1038/onc.2008.246. Oncogene. 2008. PMID: 18794885 Review.
Cited by
-
Inhibition of fatty acid synthase induces pro-survival Akt and ERK signaling in K-Ras-driven cancer cells.Cancer Lett. 2014 Oct 28;353(2):258-63. doi: 10.1016/j.canlet.2014.07.027. Epub 2014 Jul 30. Cancer Lett. 2014. PMID: 25086185 Free PMC article.
-
Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin.ACS Med Chem Lett. 2010 Jan 19;1(1):39-43. doi: 10.1021/ml900028r. eCollection 2010 Apr 8. ACS Med Chem Lett. 2010. PMID: 24900173 Free PMC article.
-
Activation of PI3Kα by physiological effectors and by oncogenic mutations: structural and dynamic effects.Biophys Rev. 2014 Mar 1;6(1):89-95. doi: 10.1007/s12551-013-0131-1. Biophys Rev. 2014. PMID: 25309634 Free PMC article.
-
Activating mutations of TOR (target of rapamycin).Genes Cells. 2011 Feb;16(2):141-51. doi: 10.1111/j.1365-2443.2010.01482.x. Epub 2011 Jan 7. Genes Cells. 2011. PMID: 21210909 Free PMC article. Review.
-
Genetic variants in the inositol phosphate metabolism pathway and risk of different types of cancer.Sci Rep. 2015 Feb 16;5:8473. doi: 10.1038/srep08473. Sci Rep. 2015. PMID: 25683757 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
